American Society of Clinical Oncology, 2026-05-26: ASCO's notice recommending against ivermectin and fenbendazole for cancer outside clinical trials, citing toxicity and the absence of clinical evidence. Its disclaimer states it is not a statement of the standard of care and does not substitute for a clinician's independent judgment.
ASCO strongly cautions that ivermectin and fenbendazole should not be used for the treatment of cancer, nor as an adjunct to established cancer therapies, outside the regulatory safeguards of a well-designed clinical trial.
American Society of Clinical Oncology, 2026-05-26: ASCO's notice recommending against ivermectin and fenbendazole for cancer outside clinical trials, citing toxicity and the absence of clinical evidence. Its disclaimer states it is not a statement of the standard of care and does not substitute for a clinician's independent judgment. F4. Professional-society position document, not a study; no funding or conflicts apply. Same document as IVA-35, re-collected for the 'forbidden' claim. This is the strongest professional discouragement in the record and the closest thing to a bar on oncologists prescribing it – but it is advice, not a prohibition: the notice's own disclaimer says 'The information herein … is not a statement of the standard of care' and 'Use of this content is voluntary and does not substitute for a clinician's independent professional judgment.' ASCO has no licensing or enforcement power over prescribing. Also filed as IVD-34, IVA-35 (claims C6, C7, F4). Study type: other.
